IMLYGIC Drug Insight

“IMLYGIC Market Size, Forecast, and Drug Insight – 2032” report provides comprehensive insights about IMLYGIC for Oncolytic Virus Therapies (OVTs) in the six major markets. A detailed picture of the IMLYGIC for OVTs in the 6MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom for the study period 2019 –2032 is provided in this report along with a detailed description of the IMLYGIC for OVTs. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the IMLYGIC market forecast analysis for OVTs in the 6MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in OVTs.

Drug Summary

IMLYGIC is a genetically modified HSV-1 designed to replicate within tumors and produce an immunostimulatory protein called granulocyte-macrophage colony-stimulating factor (GM-CSF). IMLYGIC causes cell lysis, or death, which ruptures tumors, releasing tumor-derived antigens, which along with GM-CSF, may promote an antitumor immune response. However, the exact mechanism of action is unknown.

Currently, the company is conducting a Phase II (NCT04068181) study to evaluate IMLYGIC in combination with pembrolizumab in subjects with unresectable/metastatic Stage IIIB–IVM1d melanoma and another Phase I/II (NCT02509507) trial in combination with MK-3475 in patients with advanced solid cancers. The company is also conducting trials to evaluate IMGYLIC in various indications, including breast cancer, soft tissue sarcoma, Merkel cell carcinoma, cutaneous squamous cell cancer, and other solid tumors.

Mechanism of action

Talimogene laherparepvec is oncolytic immunotherapy that is derived from HSV-1. It has been modified to replicate within tumors and to produce the immune stimulatory protein human GM-CSF. It causes the death of tumor cells and the release of tumor-derived antigens. Together with GM-CSF, it will promote a systemic antitumor immune response and an effector T-cell response.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the IMLYGIC description, mechanism of action, dosage and administration, research and development activities in OVTs.
• Elaborated details on IMLYGIC regulatory milestones and other development activities have been provided in this report.
• The report also highlights the IMLYGIC research and development activities in OVTs across the United States and Europe.
• The report also covers the patents information with expiry timeline around IMLYGIC.
• The report contains forecasted sales of IMLYGIC for OVTs till 2032.
• Comprehensive coverage of the late-stage emerging therapies for OVTs.
• The report also features the SWOT analysis with analyst views for IMLYGIC in OVTs.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

IMLYGIC Analytical Perspective by DelveInsight

In-depth IMLYGIC Market Assessment

This report provides a detailed market assessment of IMLYGIC for OVTs in the six major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom. This segment of the report provides forecasted sales data from 2023 to 2032.

IMLYGIC Clinical Assessment

The report provides the clinical trials information of IMLYGIC for OVTs covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

• In the coming years, the market scenario for OVTs is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence IMLYGIC dominance.
• Other emerging products for OVTs are expected to give tough market competition to IMLYGIC and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of IMLYGIC in OVTs.
• Our in-depth analysis of the forecasted sales data of IMLYGIC from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the IMLYGIC in OVTs.

Key Questions

• What is the product type, route of administration and mechanism of action of IMLYGIC?
• What is the clinical trial status of the study related to IMLYGIC in OVTs and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the IMLYGIC development?
• What are the key designations that have been granted to IMLYGIC for OVTs?
• What is the forecasted market scenario of IMLYGIC for OVTs?
• What are the forecasted sales of IMLYGIC in the six major countries, including the United States and Europe (Germany, France, Italy, Spain, and the United Kingdom)? 
• What are the other emerging products available and how are these giving competition to IMLYGIC for OVTs?
• Which are the late-stage emerging therapies under development for the treatment of OVTs?